AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34520538 — intervention group
Group type: COMPARATOR
Intervention: Conventional microhybrid resin composite (PA)
Number of subjects: 53
Study 34520538 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill and nanoparticulate resin composites (ABF)
Number of subjects: 53
Study 34775810 — intervention group
Group type: EXPERIMENTAL
Intervention: Video follow-up visits
Number of subjects: 24
Study 34775810 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up visits
Number of subjects: 24
Study 33629461 — intervention group
Group type: EXPERIMENTAL
Intervention: biphasic calcium phosphate covered by a cross‐linked collagen membrane (test group)
Number of subjects: 8
Study 33629461 — intervention group
Group type: COMPARATOR
Intervention: deproteinized bovine bone mineral covered by a natural collagen membrane (positive control)
Number of subjects: 8
Study 33629461 — intervention group
Group type: COMPARATOR
Intervention: no treatment (negative control)
Number of subjects: 8
Study 36121669 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab (60 mg/kg intravenously every 4 weeks for up to 100 weeks)
Number of subjects: 1619
Study 36121669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1619
Study 36121669 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenezumab
Number of subjects: 1619
Study 33833224 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (Lupron)‐induced ovarian suppression
Number of subjects: 63
Study 33833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol add‐back
Number of subjects: 63
Study 33833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone add‐back
Number of subjects: 63
Study 33833224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupron alone to progesterone conditions
Number of subjects: 63
Study 35555329 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB) therapy (amlodipine)
Number of subjects: 140
Study 35555329 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB + ACE inhibitor therapy
Number of subjects: 140
Study 35555329 — intervention group
Group type: EXPERIMENTAL
Intervention: CCB + ACE inhibitor + decreased salt intake
Number of subjects: 140
Study 35555329 — intervention group
Group type: EXPERIMENTAL
Intervention: All antihypertensive therapies
Number of subjects: 140
Study 32586396 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 80
Study 32586396 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study 35896261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin B12 500 μg/day
Number of subjects: 74
Study 35896261 — intervention group
Group type: COMPARATOR
Intervention: Oral Vitamin B12 1,500 μg/day
Number of subjects: 74
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood dust exposure
Number of subjects: 506
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: Past occupational dust exposure history
Number of subjects: 506
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: Work experience > 5 years
Number of subjects: 506
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: Using bio-fuel as energy for cooking
Number of subjects: 506
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: No occupational safety and health training
Number of subjects: 506
Study 33549074 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal wood dust exposure level
Number of subjects: 506
Study 36456016 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral azithromycin
Number of subjects: 2110
Study 36456016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2110
Study 34922212 — intervention group
Group type: EXPERIMENTAL
Intervention: Unambiguous person-derived reassurance information
Number of subjects: 398
Study 34922212 — intervention group
Group type: EXPERIMENTAL
Intervention: Unambiguous object-derived checking information
Number of subjects: 398
Study 34922212 — intervention group
Group type: COMPARATOR
Intervention: Ambiguous person-derived reassurance information
Number of subjects: 398
Study 34922212 — intervention group
Group type: COMPARATOR
Intervention: Ambiguous object-derived checking information
Number of subjects: 398
Study 34787873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation program (physical training, nutritional and lifestyle counseling)
Number of subjects: 14
Study 34787873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14
Study 33166308 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair (PR) using Mitra‐Fr data
Number of subjects: 0
Study 33166308 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair (PR) using Coapt data
Number of subjects: 0
Study 36070450 — intervention group
Group type: EXPERIMENTAL
Intervention: iTind (temporarily implanted nitinol device)
Number of subjects: 185
Study 36070450 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 185
Study 34013428 — intervention group
Group type: EXPERIMENTAL
Intervention: uniportal video‐assisted thoracoscopic surgery (uni‐VATS)
Number of subjects: 84
Study 34013428 — intervention group
Group type: COMPARATOR
Intervention: conventional 3‐port video‐assisted thoracoscopic surgery (3-port VATS)
Number of subjects: 84
Study 32795739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysulin™
Number of subjects: 110
Study 32795739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 33766702 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling every 2 weeks during therapy
Number of subjects: 61
Study 33766702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 61
Study 33766702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (nutritional counseling)
Number of subjects: 61
Study 32631586 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol 1 mg combined with drospirenone 2 mg
Number of subjects: 80
Study 32631586 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 32908086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 640
Study 32908086 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 640
Study 33836635 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) and histone deacetylase inhibitors (HDACi) combination
Number of subjects: 0
Study 32930040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for chronic fatigue syndrome
Number of subjects: 995
Study 33630043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 312
Study 33630043 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 312
Study 32419647 — intervention group
Group type: EXPERIMENTAL
Intervention: High worry condition
Number of subjects: 804
Study 32419647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low worry condition
Number of subjects: 804
Study 32419647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 804
Study 616120483 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresh Contacts
Number of subjects: 18
Study 616120483 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane Balance
Number of subjects: 18
Study 616120483 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive Plus
Number of subjects: 18
Study 616120483 — intervention group
Group type: EXPERIMENTAL
Intervention: All products tested (Optive Plus, Refresh Contacts, Systane Balance)
Number of subjects: 18
Study 33407248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for outdoor exposure reduction
Number of subjects: 211
Study 33407248 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for both outdoor and indoor exposure reduction
Number of subjects: 211
Study 33407248 — intervention group
Group type: COMPARATOR
Intervention: No intervention for desert dust events
Number of subjects: 211
Study 33136831 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 651
Study 33234323 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuomotor therapy (active)
Number of subjects: 10
Study 33234323 — intervention group
Group type: COMPARATOR
Intervention: Passive motion (sham)
Number of subjects: 10
Study 34362348 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation forceps
Number of subjects: 177
Study 34362348 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 177
Study 35686576 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary graded exposure treatment (GET Living)
Number of subjects: 68
Study 35686576 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary pain management (Control)
Number of subjects: 68
Study 32989170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives (COC) (Triphasil or Nordette)
Number of subjects: 130
Study 32989170 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable Norethisterone Enanthate (Net-En)
Number of subjects: 130
Study 32989170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Contraceptive Vaginal Ring (CCVR; NuvaRing)
Number of subjects: 130
Study 32989170 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (COC)
Number of subjects: 130
Study 36480272 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person coaching
Number of subjects: 224
Study 36480272 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual coaching
Number of subjects: 224
Study 36480272 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study 33596989 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant unexplained indirect hyperbilirubinemia (cases)
Number of subjects: 150
Study 33596989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no significant unexplained indirect hyperbilirubinemia)
Number of subjects: 150
Study 33596989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases with UTI
Number of subjects: 150
Study 33596989 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI positive patients
Number of subjects: 150
Study 32634745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 144
Study 32634745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 34514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 68
Study 34514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye masks
Number of subjects: 68
Study 34514653 — intervention group
Group type: COMPARATOR
Intervention: Eye masks with earplugs
Number of subjects: 68
Study 33481828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment (PAT)
Number of subjects: 34
Study 33481828 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (active control)
Number of subjects: 34
Study 32067836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure intervention
Number of subjects: 8052
Study 32067836 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure intervention
Number of subjects: 8052
Study 36054480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Number of subjects: 5661
Study 36054480 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg twice daily)
Number of subjects: 5661
Study 36054480 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analysis for events meeting CEC definitions
Number of subjects: 5661
Study 33647529 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated BFRT (Delfi's Personalized Tourniquet System) at 30% 1RM
Number of subjects: 34
Study 33647529 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized BFRT (B-Strong™ device) at 30% 1RM
Number of subjects: 34
Study 33647529 — intervention group
Group type: COMPARATOR
Intervention: High-load resistance exercise at 80% 1RM
Number of subjects: 34
Study 35543939 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Siguan points (Hegu [LI 4] and Taichong [LR 3]), 30 min each time, once a day, 5 times per week for 4 weeks
Number of subjects: 110
Study 35543939 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine hydrochloride capsule, 10 mg a day for 4 weeks
Number of subjects: 110
Study 33239872 — intervention group
Group type: EXPERIMENTAL
Intervention: New Endurance Test (ET) starting at 75% of WMAX, increasing stepwise by 3% every 2 minutes until exhaustion (Study A)
Number of subjects: 33
Study 33239872 — intervention group
Group type: EXPERIMENTAL
Intervention: New Endurance Test (ET) starting at 70% of WMAX, increasing linearly by 1% per minute (Study B)
Number of subjects: 33
Study 33239872 — intervention group
Group type: COMPARATOR
Intervention: Standard Endurance Test (ET)
Number of subjects: 33
Study 35947864 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Solution Focused Therapy (BSFT), 5 sessions over 3 months
Number of subjects: 30
Study 35947864 — intervention group
Group type: COMPARATOR
Intervention: Standard care for schizophrenia
Number of subjects: 30
Study 34432011 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 107
Study 34432011 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107
Study 32933504 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 40 mg once daily
Number of subjects: 59
Study 32933504 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia bellerica (TBE) 500 mg twice daily
Number of subjects: 59
Study 32933504 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia bellerica (TBE) 1000 mg twice daily
Number of subjects: 59
Study 35417958 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy (1000 mg ferric carboxymaltose in 100 mL saline, infused slowly over 15 min 7 days before surgery)
Number of subjects: 80
Study 35417958 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 80
Study 35417958 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL saline, infused slowly over 15 min 7 days before surgery)
Number of subjects: 80
Study 35417958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33493160 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 66
Study 33493160 — intervention group
Group type: COMPARATOR
Intervention: Active control group (aCG)
Number of subjects: 66
Study 32298023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration
Number of subjects: 156
Study 35263434 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine plus amiodarone
Number of subjects: 154
Study 35263434 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus amiodarone
Number of subjects: 154
Study 33823738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 60
Study 33823738 — intervention group
Group type: COMPARATOR
Intervention: Trimetazidine
Number of subjects: 60
Study 32587723 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-care educational programme with foot-care tools, 3-5 sessions over 2 months
Number of subjects: 110
Study 32587723 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 110
Study 32587723 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-care educational programme
Number of subjects: 110
Study 34579112 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (10 g/day)
Number of subjects: 24
Study 34579112 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 10 g/day)
Number of subjects: 24
Study 33163534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile video call‐guided
Number of subjects: 90
Study 33163534 — intervention group
Group type: COMPARATOR
Intervention: Voice call‐guided
Number of subjects: 90
Study 33163534 — intervention group
Group type: COMPARATOR
Intervention: Non‐guided
Number of subjects: 90
Study 36065810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nelonemdaz (2750 mg)
Number of subjects: 209
Study 36065810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nelonemdaz (5250 mg)
Number of subjects: 209
Study 36065810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 34391264 — intervention group
Group type: EXPERIMENTAL
Intervention: Knitting program (8-week duration) with bi-weekly 20-min group sessions and daily 20-min home sessions
Number of subjects: 37
Study 34391264 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet (control group)
Number of subjects: 37
Study 32592693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination‐indicated cerclage
Number of subjects: 34
Study 35507508 — intervention group
Group type: EXPERIMENTAL
Intervention: CoVLP+AS03 vaccine
Number of subjects: 24141
Study 34950944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening (home tracing and intensive HIV/TB screening)
Number of subjects: 4459
Study 34950944 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC, clinic referral letters)
Number of subjects: 4459
Study 34950944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening
Number of subjects: 4459
Study 34950944 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 4459
Study 36100263 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU for 56 days postoperatively
Number of subjects: 614
Study 36100263 — intervention group
Group type: COMPARATOR
Intervention: In-hospital postoperative thromboprophylaxis only
Number of subjects: 614
Study 36100263 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU
Number of subjects: 614
Study 34170798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent nursing intervention program focusing on modifiable risk factors
Number of subjects: 1749
Study 34170798 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1749
Study 34170798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent nursing intervention program
Number of subjects: 1749
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo delivered by VEx
Number of subjects: 54
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: No-treatment delivered by VEx
Number of subjects: 54
Study 33230290 — intervention group
Group type: COMPARATOR
Intervention: Placebo delivered by text-only control
Number of subjects: 54
Study 33230290 — intervention group
Group type: COMPARATOR
Intervention: No-treatment delivered by text-only control
Number of subjects: 54
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy manipulation (placebo or no-treatment)
Number of subjects: 54
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: VEx regardless of treatment
Number of subjects: 54
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 54
Study 33230290 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective pain ratings
Number of subjects: 54
Study 35564596 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (two doses of IM dexamethasone 12 mg, 12 hours apart, 24 hours prior to surgery)
Number of subjects: 189
Study 35564596 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 189
Study 33526149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Support Programs (PSPs) awareness
Number of subjects: 385
Study 33526149 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 385
Study 33526149 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for nonadherence
Number of subjects: 385
Study 32086819 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (single infusion)
Number of subjects: 10
Study 33782926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold endoscopic mucosal resection (EMR)
Number of subjects: 0
Study 33782926 — intervention group
Group type: COMPARATOR
Intervention: Hot endoscopic mucosal resection (EMR)
Number of subjects: 0
Study 33474955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 106
Study 33474955 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 106
Study 34807716 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (third dose)
Number of subjects: 117
Study 34807716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 32690203 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 692
Study 32690203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone delivery by a trained navigator
Number of subjects: 692
Study 32690203 — intervention group
Group type: EXPERIMENTAL
Intervention: Web + Phone intervention
Number of subjects: 692
Study 32690203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 692
Study 36343880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Family-Based Treatment (FBT)
Number of subjects: 150
Study 36343880 — intervention group
Group type: COMPARATOR
Intervention: Guided self-help Family-Based Treatment (gshFBT)
Number of subjects: 150
Study 33402353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ironbark: Standing Strong and Tall programme
Number of subjects: 0
Study 33402353 — intervention group
Group type: COMPARATOR
Intervention: Healthy Community programme
Number of subjects: 0
Study 32371430 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 728
Study 32371430 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab reference product (RP)
Number of subjects: 728
Study 32371430 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327 or RP (with treatment switching)
Number of subjects: 728
Study 35552824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxabact (lyophilized O. formigenes formulation), administered orally, twice daily for 52 weeks.
Number of subjects: 25
Study 35552824 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally, twice daily for 52 weeks.
Number of subjects: 25
Study 32909168 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 187